The optimality of different strategies for supplemental staging of non-small-cell lung cancer: A health economic decision analysis

Value in Health

Volumn 16, Issue 1, 2013, Pages 57-65

  Søgaard, Rikke ^a   Fischer, Barbara Malene B ^b   Mortensen, Jann ^b,c   Rasmussen, Torben R ^d   Lassen, Ulrik ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cost effectiveness evaluation; decision analysis; diagnostic radiology; health economic modeling; lung cancer; probabilistic sensitivity analysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DENMARK; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; ENDOBRONCHIAL ULTRASONOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; PREVALENCE; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HEALTH CARE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURGICAL MORTALITY; THORACOTOMY; THORAX RADIOGRAPHY; TRANSTHORACIC BIOPSY; UNCERTAINTY;

AGED; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DECISION TREES; DENMARK; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDIASTINOSCOPY; MODELS, ECONOMIC; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; QUALITY OF LIFE; REGISTRIES;

EID: 84872731075     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.09.007     Document Type: Article

References (32)

1. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
2. P. De Leyn, D. Lardinois, and P.E. Van Schil ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer Eur J Cardiothorac Surg 32 2007 1 8
3. J. Schreyogg, J. Weller, and T. Stargardt Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer J Nucl Med 51 2010 1668 1675
4. R. Søgaard, B.M. Fischer, and J. Mortensen Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial Eur J Nucl Med Mol Imaging 38 2011 802 809
5. A.H. Briggs, K. Claxton, and M.J. Sculpher Decision modelling for health economic evaluation 2006 Oxford University Press Oxford
6. R. Søgaard, and B.M. Fisher Modelling Cost-Effectiveness of Different Strategies for Preoperative Staging of Lung Cancer: CAST Technical Report 2010 University of Southern Denmark Odense, Denmark
7. F.C. Detterbeck, M.A. Jantz, and M. Wallace Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed.) Chest 132 Suppl 2007 202S 220SS
8. S.R. Puli, J. Batapati Krishna Reddy, and M.L. Bechtold Endoscopic ultrasound: its accuracy in evaluating mediastinal lymphadenopathy? A meta-analysis and systematic review World J Gastroenterol 14 2008 3028 3037
9. P. Gu, Y.Z. Zhao, and L.Y. Jiang Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis Eur J Cancer 45 2009 1389 1396
10. G.J. Herder, H. Kramer, and O.S. Hoekstra Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study J Clin Oncol 24 2006 1800 1806
11. C.E. Reed, D.H. Harpole, and K.E. Posther Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer J Thorac Cardiovasc Surg 126 2003 1943 1951
12. Cerfolio RJ, Ojha B, Bryant AS, et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004;78:1017-1023; discussion 17-23.
13. B.S. Halpern, C. Schiepers, and W.A. Weber Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion Chest 128 2005 2289 2297
14. W. De Wever, S. Ceyssens, and L. Mortelmans Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT Eur Radiol 17 2007 23 32
15. W. Yang, Z. Fu, and J. Yu Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer Lung Cancer 61 2008 35 43
16. B. Fischer, U. Lassen, and J. Mortensen Preoperative staging of lung cancer with combined PET-CT N Engl J Med 361 2009 32 39
17. Danish Lung Cancer Group. Annual Report of the Danish Lung Cancer Registry 2009. Odense, Denmark: Danish Lung Cancer Group, 2010.
18. W.E. Barlow Overview of methods to estimate the medical costs of cancer Med Care 47 Suppl 2009 S33 S36
19. L. Crino, W. Weder, and J. van Meerbeeck Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v103 v115
20. G. D'Addario, and E. Felip Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 4 2009 68 70
21. G. D'Addario, M. Fruh, and M. Reck Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v116 v119
22. J. Goffin, C. Lacchetti, and P.M. Ellis First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review J Thorac Oncol 5 2010 260 274
23. J.S. Hoch, A.H. Briggs, and A.R. Willan Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis Health Econ 11 2002 415 430
24. A.A. Stinnett, and J. Mullahy Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis Med Decis Making 18 Suppl 1998 S68 S80
25. C. McCabe, K. Claxton, and A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744
26. K. Claxton The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies J Health Econ 18 1999 341 364
27. Excellence NIfC, ed. National Institute for Health and Clinical Excellence. The Diagnosis and Treatment of Lung Cancer. London: NICE, 2005.
28. K. Alzahouri, C. Lejeune, and M.C. Woronoff-Lemsi Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective Clin Radiol 60 2005 479 492
29. I. Bradbury, E. Bonell, and J. Boynton Positron Emission Tomography (PET) Imaging in Cancer Management HTBf Scotland, 2002 Health Technology Board for Scotland Glasgow, Scotland
30. M. Dietlein, K. Weber, and A. Gandjour Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results Eur J Nucl Med 27 2000 1598 1609
31. P. Verboom, H. van Tinteren, and O.S. Hoekstra Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study Eur J Nucl Med Mol Imaging 30 2003 1444 1449
32. G.R. Simon, and A. Turrisi Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd ed.) Chest 132 2007 324S 339S